Because potent inhibitors of CYP3A4 have raised
lercanidipine levels by 15-fold the manufacturers predict that
erythromycin will raise
lercanidipine levels.
Concurrent use is contraindicated. Other
macrolides may also interact, although it seems unlikely that they all will, see
macrolides.